<DOC>
	<DOCNO>NCT01097369</DOCNO>
	<brief_summary>Primary Objective : To determine incidence , titer type anti-rasburicase antibody context hypersensitivity reaction ( ) loss uricolytic activity occur patient relapsed leukemia/lymphoma re-treated rasburicase experience hypersensitivity reaction loss uricolytic activity .</brief_summary>
	<brief_title>Elitek ( Rasburicase ) Immuno-Monitoring Study</brief_title>
	<detailed_description />
	<mesh_term>Tumor Lysis Syndrome</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>Inclusion criterion : 1 . Previous history rasburicase exposure history administration repeat ( 2nd ) series rasburicase injection ( context supportive care relapse leukemia/lymphoma ) subsequent development either hypersensitivity reaction ( HSR ) loss uricolytic activity ( defined failure achieve uric acid level &lt; = 7.5 mg/dl measure 48 hour first rasburicase injection ) . 1 . A severe hypersensitivity reaction ( NCI Grade 3 , 4 5 ) define : Allergic reaction ; allergy ; anaphylactic shock ; bronchospasm ; bullous skin eruption ; dermatitis exfoliative ; drug hypersensitivity ; dyspnea ; hypotension ; hypoxia ; rash ; rash erythematous ; rash maculopapular , urticaria ; pyrexia/fever ; edema ; chest discomfort ; hypersensitivity ( NOS ) ; pharynx discomfort ; hoarseness ; pharyngeal erythema ; pruritus ; erythema ; localize exfoliation ; rash papular ; swell ¿ face/facial ; toxic skin eruption ; hot flush ; flushing ; rash macular ; rash pruritic ; pruritus allergic . 2 . Loss uricolytic activity define : uric acid level &gt; 7.5 mg/dl measure 48 hour first rasburicase injection¿ , time point coincident administration third dose rasburicase ( within second course treatment agent ) . 2 . Patients receive least 2 dos rasburicase repeat ( 2nd ) administration event loss uricolytic activity . At least 1 dose rasburicase administer repeat ( 2nd ) administration diagnosis HSR . Exclusion criterion : 1 . Concomitant treatment human IV immunoglobulin ( IVIG ) 2 . Concomitant treatment TNFalpha antagonists/inhibitors , i.e . adalimumab , infliximab , etanercept 3 . Concomitant treatment Interferonalpha ( IFNalpha ) 4 . Unwillingness inability comply requirement protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>